NTLA - Intellia Therapeutics, Inc.
IEX Last Trade
11.81
-0.090 -0.762%
Share volume: 25,110
Last Updated: Fri 27 Dec 2024 05:30:16 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$11.90
-0.09
-0.76%
Fundamental analysis
18%
Profitability
25%
Dept financing
5%
Liquidity
75%
Performance
0%
Performance
5 Days
-0.41%
1 Month
-18.19%
3 Months
-41.42%
6 Months
-47.40%
1 Year
-62.74%
2 Year
-65.55%
Key data
Stock price
$11.81
DAY RANGE
$11.69 - $12.30
52 WEEK RANGE
$12.21 - $34.87
52 WEEK CHANGE
-$62.07
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: John M. Leonard
Region: US
Website: intelliatx.com
Employees: 600
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: intelliatx.com
Employees: 600
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis. The firm has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells.
Recent news